P555: A PHASE 1B/2 STUDY OF THE CD123-TARGETING ANTIBODY-DRUG CONJUGATE PIVEKIMAB SUNIRINE (IMGN632) IN COMBINATION WITH VENETOCLAX (VEN) AND AZACITIDINE (AZA) FOR PATIENTS WITH CD123-POSITIVE AML

• N. G. Daver,
• P. Montesinos,
• A. Aribi,
• G. Martinelli,
• J. Altman,
• G. Roboz,
• E. S. Wang,
• P. W. Burke,
• D. Jeyakumar,
• R. B. Walter,
• D. J. DeAngelo,
• H. P. Erba,
• A. Advani,
• L. Gastaud,
• X. Thomas,
• E. Todisco,
• N. Pemmaraju,
• L. Mendez,
• A. de la Fuente,
• G. Gaidano,
• A. Curti,
• N. Boissel,
• C. Recher,
• C. Schliemann,
• P. Vyas,
• C. M. Sloss,
• J. Wang,
• K. A. Malcolm,
• P. A. Zweidler-McKay,
• K. L. Sweet

Affiliations

N. G. Daver

1 Department of Leukemia, The University of Texas MD Anderson, Houston, United States of America

P. Montesinos

2 Hospital Universitari i Politècnic La Fe, Valencia, Spain

A. Aribi

3 Gehr Family Center for Leukemia Research, City of Hope, Duarte, United States of America

G. Martinelli

4 Department of Experimental, Diagnostic and Specialty Medicine, Institute of Hematology “L. e A. Seràgnoli”, Bologna, Italy

J. Altman

5 Division of Hematology and Oncology, Northwestern University Feinberg School of Medicine, Chicago

G. Roboz

6 Division of Hematology & Medical Oncology, Weill Cornell Medicine/New York Presbyterian Hospital, New York

E. S. Wang

7 Roswell Park Comprehensive Cancer Center, Buffalo

P. W. Burke

8 Department of Internal Medicine, Division of Hematology/Oncology, University of Michigan, Ann Arbor

D. Jeyakumar

9 University of California Irvine, Chao Family Comprehensive Cancer Center, Orange

R. B. Walter

10 Fred Hutchinson Cancer Research Center, Seattle

D. J. DeAngelo

11 Department of Medical Oncology, Harvard Medical School, Dana-Farber Cancer Institute, Boston

H. P. Erba

12 Division of Hematologic Malignancies and Cellular Therapy, Duke University, Durham

A. Advani

13 Taussig Cancer Institute, Cleveland Clinic, Cleveland, United States of America

L. Gastaud

14 Medical Oncology Department, Antoine Lacassagne Hospital, Nice

X. Thomas

15 Department of Hematology, Hospices Civils de Lyon, Lyon-Sud Hospital, Lyon, France

E. Todisco

16 Division of Onco-Hematology, European Institute of Oncology IRCCS, Milano, Italy

N. Pemmaraju

1 Department of Leukemia, The University of Texas MD Anderson, Houston, United States of America

L. Mendez

17 Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, United States of America

A. de la Fuente

18 MD Anderson Cancer Center Madrid, Madrid, Spain

G. Gaidano

19 Division of Hematology, Department of Translational Medicine, Università del Piemonte Orientale, Novara

A. Curti

20 IRCCS Azienda ospedaliero-universitaria di Bologna, Istituto di Ematologia “Seràgnoli”, Bologna, Italy

N. Boissel

21 Université de Paris, Service Hématologie, Hôspital Saint-Louis, Paris

C. Recher

22 Service d’Hématologie, CHU de Toulouse - Institut Universitaire du Cancer Toulouse Oncopole, Toulouse, France

C. Schliemann

23 Department of Medicine A, Hematology, Oncology and Pneumology, University Hospital Muenster, Muenster, Germany

P. Vyas

24 MRC Molecular Haematology Unit, Weatherall Institute of Molecular Medicine, University of Oxford, Oxford NIHR Biomedical Research Centre, and Oxford University Hospitals NHS Trust, Oxford, United Kingdom

C. M. Sloss

25 ImmunoGen, Inc., Waltham

J. Wang

25 ImmunoGen, Inc., Waltham

K. A. Malcolm

25 ImmunoGen, Inc., Waltham

P. A. Zweidler-McKay

25 ImmunoGen, Inc., Waltham

K. L. Sweet

26 Department of Malignant Hematology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, United States of America